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Methylmercury (MeHg) affects several parameters ofcholinergic function. These alterations are
thought to play a role in MeHg neurotoxicity. In vitro experiments have indicated that MeHg
acts as a strong competitive inhibitor ofradioligand binding to muscarinic cholinergic receptors
(mAChRs) in rat brain. Furthermore, rat brain mAChRs share several pharmacologic character-
istics ofsimilar receptors present on lymphocytes. Using the muscarinic antagonist [3H]quinu-
clidinyl benzilate (QNB) to label receptors, we investigated the in vivo interactions of MeHg
with rat brain mAChRs. We also investigated whether MeHg-induced central mAChR changes
are reflected bysimilar alterations in spleniclymphocytes. Exposure to low doses ofMeHg-0.5
or 2 mg/kg/day in drinking water-for 16 days significantly increased (20-44% of control)
mAChRs density (BE ) in the hippocampus and cerebellum without affecting receptor affinity
(Kd). The effect ofMeHgdid not occurimmediatelry itwas not apparent until 2 weeks afterthe
termination oftreatiment. No significant changes in [3H]QNB binding were observed in the
cerebral cortex. In spleniclymphocytes, mAChRdensitywasremarkably increased (95-198% of
control) by day 14 of MeHg exposure and remained enhanced 14 days itfter the cessation of
treatment. These results suggest up-regulation ofmAChRs in selected brain regions (hippocam-
pus and cerebellum) after prolonged low-level ingestion ofMeHg in rats. These cerebral effects
are delayed in onset and are preceded by a marked increase in density ofmAChRs on lympho-
cytes. In chronic MeHg exposure, peripheral lymphocytes may represent a sensitive target for
the interaction of MeHg with mAChRs and, therefore, may be predictive indicators oflater
adaptive response involving cerebral mAChRs. Additionally, the effect ofMeHg on lymphocyte
mAChRs in vivo indicates that this receptor system should be investigated fiurther as apossible
target for MeHg immunotoxicity. Key words: biomarker, brain, cholinergicsystem, lymphocyte,
methylmercury, muscarinic receptor, neurotoxicity. Environ Health Perspect 108:29-33 (2000).
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Methylmercury (MeHg) is a ubiquitous and
hazardous environmental contaminant.
Catastrophic episodes of MeHg poisoning
due to accidents or to the consumption of
food contaminated by high concentrations of
MeHg have been described (1,2). Because
ingested MeHg is almost completely absorbed
from the digestive tract and easily accumu-
lates in the brain, chronic low-level dietary
intake of MeHg also poses a significant toxi-
cologic problem. Excessive MeHg intake has
been reported in fish-eating communities in
Greenland, the Faroe Islands, the Seychelles,
the Madeira Basin (in the Amazon region),
and New Zealand (3-5). There is concern
about the risks to human nervous system
development associated with such exposures.
Several observations indicate that the imma-
ture brain is highly susceptible to MeHg toxi-
city (6). In prenatal exposure, deficits in
infant brain development have been associat-
ed with MeHg levels that cause few, if any,
symptoms or signs oftoxicity in adults (7).
Research data indicate that the cholinergic
Surstem is one of multiple targets for MeHg
neurotoxicity. In vitro MeHg inhibits choline
uptake and choline acetyltransferase (ChAT)
activity while exerting both stimulatory and
inhibitory effects on acetylcholine (ACh)
release from central (8) and peripheral (9)
nerve endings. Additionally, MeHg inhibits
radioligand binding to brain cholinergic
(nicotinic and muscarinic) receptors in a com-
petitive manner (10-12). The results of in
vivo studies support these observations. Long-
term administration of MeHg slightly but
uniformly decreases cerebral ChAT activity
(13). As a result, the rate ofACh synthesis
and the levels of regional ACh are decreased
(14,15). In rats, prenatal exposure to MeHg
reduced muscarinic binding in the developing
brain (16).
Radioligand binding studies have also
documented the presence ofcholinergic mus-
carinic receptors (mAChRs) in nonexcitable
tissues, for example, splenic or circulating
lymphocytes, from both rats (17,18) and
humans (19,20). Rat lymphocyte mAChRs
share several pharmacologic characteristics of
similar receptors present in brain tissue (21).
Muscarinic binding was modulated by
cholinergic and anticholinergic compounds
in a similar manner in brain and lymphocytes
(22). In comparative assays using V3H]quinu-
clidinyl benzilate ([3H]QNB) to label
mAChRs, a 14-day exposure to the organo-
phosphate pesticide disulfoton (an acetyl-
cholinesterase inhibitor) caused a significant
decrease (25-35%) in mAChRs density in
brain areas (cerebral cortex, hippocampus,
striatum, and medulla pons), as well as in
lymphocytes (23). During disulfoton expo-
sure, the decline of mAChR density in lym-
phocytes paralleled those observed in brain
(23). These findings suggest that lympho-
cytes may serve as peripheral markers of the
central mAChR changes induced by xenobi-
otics. Application of mAChR assays using
peripheral blood lymphocytes has recently
been described in patients with disease states
that are likely associated with alteration of
the central cholinergic receptors (24,25).
There is growing evidence from animal
and cell culture studies that MeHg may
adversely affect the immune system (26).
Low concentrations of MeHg (0.6-5 pM)
cause dose-dependent changes and cell death
in human T cells (26). These effects are
apparently induced by MeHg by apoptotic
mechanisms that also appear to play a major
role in MeHg neurotoxicity (27).
This study investigated the effects ofpro-
longed low-dose MeHg exposure on the
mAChRs present in rats in three brain
regions (cerebral cortex, hippocampus, and
cerebellum) and on splenic lymphocytes. The
discussion relates the results to neurotoxic
and immunotoxic effects ofMeHg exposure,
and to the prospect of using lymphocyte
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mAChRs as surrogate indicators of mAChR
changes induced byMeHg in brain tissue.
Materials and Methods
Chemicals. [3H]QNB (49 Ci/mmol) and
scintillation fluid Biofluor were obtained
from NEN Life Sciences Products (Boston,
MA). Methylmercury (II) hydroxide was
obtained from Alfa (Karlsruhe, Germany),
and all other chemicals were from Sigma
Chimica (Milan, Italy).
Animals and treatment. Adult female
Sprague-Dawley rats (200-250 g) were
obtained from Charles River (Calco, Italy).
Animals were randomized to treatment
groups and housed one per cage under con-
stant conditions of temperature, humidity,
and photocycle (12-hr light/12-hr dark) for
at least 1 week before study. A commercial
rat diet (4RF21; Mucedola, Settimo
Milanese, Italy) and water were given
adlibitum.
Rats were given MeHg for 16 consecu-
tive days. Three groups of animals received
MeHg in their drinking water at nominal
concentrations of 0, 2.5, and 10 pg/mL,
respectively. Fresh MeHg solutions were pre-
pared daily from a 1 M stock solution of
methylmercury (II) hydroxide in water.
Water consumption and body weight were
recorded daily during the study. MeHg
intake in the two groups ofMeHg-exposed
rats averaged (mean ± SD) 0.45 ± 0.052 and
1.8 ± 0.212 mglkg/day, respectively. Rats
were sacrificed by decapitation either imme-
diately or 14 days after the termination of
MeHg treatment. The spleens and brains
were rapidly removed and placed in 32 mL
Hank's buffer (without calcium and magne-
sium; pH 7.5) on ice. Three brain areas
(cerebral cortex, cerebellum, and hippocam-
pus) were dissected, weighed, and then
stored at -80°C until receptor binding assays
were performed.
All experiments complied with European
Council Directive 86/609/EEC on the care
and use oflaboratoryanimals (28).
Isolation ofsplenic lymphocytes. The
spleen was teased apart with forceps in
Hank's buffer, and 8 mL cell suspension was
layered on 3 mL Histopaque 1,083 (Sigma
Chimica, Milan, Italy) according to the
method ofBoyum (29). After centrifugation
at 400g for 30 min, the layer containing
lymphocytes was transferred to another plas-
tic tube, resuspended in Hank's buffer, and
washed three times by centrifugation (200g
for 10 min). The cells were resuspended in
the same buffer and counted on a Coulter
counter (Instrumentation Laboratory,
Monza, Italy).
Preparation ofbrain tissue membranes.
Membranes were prepared by homogeniza-
tion with Polytron (Braun, Germany) for 20
sec. Brain areas were homogenized in 20 vol-
umes ice-cold 0.05 M Na/K phosphate
buffer (pH 7.4). The homogenate was cen-
trifuged three times at 49,000g for 10 min
at 40C.
[3H]QNB binding in lymphocytes.
Saturation binding of [3H]QNB to lym-
phocytes was performed as described by
Fitzgerald and Costa (23). Briefly, 2 million
lymphocytes were incubated in a range of
[3H]QNB concentrations (7.5-240 nM)
and Hank's buffer in a total volume of 0.5
mL in plastic tubes. After 60 min incubation
under gentle shaking at 27°C, the reaction
was stopped by adding 3 mL ice-cold phos-
phate-buffered saline (PBS); samples were
rapidly filtered through Whatman GF/C fil-
ters (Whatman, Maidstone, Kent, UK)
using a Brandel cell harvester (Emanuele
Mires, Milan, Italy) and washed three times
with 3 mL ice-cold PBS. Filters were then air
dried and counted for radioactivity in 3 mL
Biofluor in a Packard 1900 CA scintillation
counter (Packard, Milan, Italy). Atropine
Table 1. Muscarinic receptor binding in MeHg-treated rats: end oftreatment.a
Cerebral cortex Hippocampus Cerebellum Lymphocytes
(mean + SE) (mean ± SE) (mean ± SE) (mean ± SE)
Control
Bmax 2,016 204 1,505 ±213 157 ± 13 87 ±33
Kd 0.34 0.01 0.19 ± 0.03 0.05 ± 0.01 67 ± 17
nH 1.13±0.02 1.12±0.03 0.95±0.03 0.98±0.01
MeHg (0.5 mg/kg/day)
Bmax 2,296 90 1,623 ±262 167 ± 21 170* ±34
Kd 0.37±0.04 0.19±0.01 0.05±0.01 63±9
nH 1.11 ± 0.01 1.06 ± 0.03 0.96 ±0.01 0.99 ± 0.06
MeHg (2 mg/kg/day)
Bmax 2,066 162 1,679 ±228 162 ±33 259* ±58
Kd 0.32±0.04 0.19±0.02 0.05±0.01 80±10
nH 1.11 ±0.01 1.10 ± 0.02 0.93± 0.01 0.92± 0.02
Abbreviations: B ax, receptor density expressed as fmol/mg protein (brain) or fmol/106 cells (lymphocytes); Kd, receptor
affinity(nM); nH= Hill coefficient.
fRats were treated with MeHg in drinking water for 16 days and sacrificed immediately after termination of exposure.
Values are the mean ± SE of three separate experiments in which tissues from four rats were pooled. *p < 0.05, statisti-
cally different within a single experiment comparing the [3HIGNB saturation curve from MeHg-treated rats with its con-
current control curve.
(10-4 M) was added to halfofthe tubes for
estimation ofspecific binding, defined as the
difference between binding in the absence
and the presence of atropine. In a series of
preliminary experiments, the influence of
different incubation times and temperatures
on [3H]QNB binding was tested. Each sam-
ple was assayed in triplicate and data were
expressed as fmol/106 cells.
[3H]QNB binding in brain membranes.
Saturation [3H]QNB bindingwas performed
in membrane preparations from cerebral cor-
tex, cerebellum, and hippocampus by the
method ofYamamura and Snyder (30), as
previously described (22,31). Atropine (10-5
M) was added 10 min before [3H]QNB to
halfofthe tubes for estimation ofnonspecific
binding. Samples were incubated with
[3H]QNB concentrations ranging from
0.025 to 1 nM. Binding assaywas carried out
as described forlymphocytes. Protein content
was determined by the method of Lowry et
al. (32). Data were expressed as femtomoles
permilligram ofprotein.
Analysis ofdata. Receptor density (Bma)
and affinity (defined as the reciprocal ofthe
dissociation constant, Kd) were estimated by
nonlinear regression analysis ofbinding data
according to the methods described by
Bylund and Yamamura (33). The Hill coef-
ficients (nH) were derived from
log[BI(Bmax - B)] = nHX logF-logKd,
where B is the concentration of bound lig-
and at any given concentration offree ligand
(I) (33).Analysis ofvariance for continuous-
by-class effects was used to test statistical dif-
ferences in saturation curve profiles between
MeHg-treated and control rats. Statistical
analysis was performed using the SAS system
Table 2. Muscarinic receptor binding in rats 14
days aftertermination oftreatmentwith MeHg.a
Cerebral Hippo- Cere- Lympho-
cortex campus bellum cytes
(mean) (mean) (mean) (mean)
Control
Bmax 1,868 1,345 145 110
Kd 0.47 0.30 0.05 55
nH 1.09 1.12 0.89 1.02
MeHg (0.5 mg/kg/day)
Bmax 2,077 1,418 174* 190*
Kd 0.53 0.34 0.05 49
nH 1.09 1.11 0.93 0.94
MeHg (2 mg/kg/day)
Bmax 1,969 1,934* 184* 274*
Kd 0.36 0.37 0.05 50
nH 1.11 1.11 0.91 1.14
Abbreviations: 8nx, receptor density expressed as
fmol/mg protein (brain} or fmol/106 cells (Ilymphocytes);
Kd, receptor affinity(nM); nH= Hill coefficient.
'Values are the mean of two separate experiments in
which tissues from four rats were pooled. *p < 0.05, sta-
tistically different within a single experiment comparing
the I3HIQNB saturation curve from MeHg-treated rats
with its concurrent control curve.
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computer program (SAS Institute, Inc.,
Cary, NC).
Results
Effects ofexposure. Rats given 0.5 or 2.0
mg/kg/day MeHg in their drinking water
remained physically normal and were behav-
iorally similar to controls. Daily water con-
sumption and body weight gain were similar
in controls and in MeHg-treated animals
(data not shown). The absorption of mer-
cury was not measured. In separate experi-
ments on pregnant rats given 0.5 mg/kg
MeHg in the drinking water from day 7 of
gestation until day 7 of lactation, we mea-
sured total mercury concentrations of
approximately 1 pg/g in the brain and cere-
bellum ofthe adult animals (34).
/3H]QNB binding in brain. The experi-
ments performed immediately after the 16-
day exposure period showed no significant
differences in [3H]QNB binding between
control and MeHg-treated rats in any of the
brain regions (cerebral cortex, hippocampus,
and cerebellum) examined (Table 1).
However, binding was significantly increased
in the hippocampus and cerebellum of the
MeHg-exposed animals allowed to survive 14
days after termination oftreatment (Table 2).
Data from representative experiments illus-
trating the delayed effect ofMeHg on recep-
tor binding in the cerebellum are shown in
Figure 1. In the postexposure period, cerebel-
lar mAChRs density (Bmax) was increased by
20 and 27% in rats treated with 0.5 and 2
mg/kg MeHg, respectively. In hippocampus,
a 44% increase in the Bmax was observed in
rats in the 2 mg/kg group, whereas no signifi-
cant changes in [3H]QNB binding were seen
in the animals given the lower (0.5 mg/kg)
MeHg dose. Muscarinic binding was not
affected in the cerebral cortex at any of the
MeHg doses tested (Tables 1 and 2).
In all brain areas, MeHg did not affect
the affinity of mAChRs, as indicated by the
dissociation constant values (ld) measured
either immediately or 14 days after termina-
tion ofexposure (Tables 1 and 2). The Hill
coefficients (nH) were close to unit
(0.89-1.13) in both control and MeHg-
treated rats, suggesting homogeneous affinity
ofthe labeled receptors for the ligand.
2W0.







[3H]QNB binding in splenic lympho-
cytes. In rats given MeHg, significant
increases in splenic lymphocyte [3H]QNB
binding were observed both immediately
after exposure (Table 1) and 14 days after
the cessation of treatment (Table 2). The
effects of MeHg were dose dependent.
Lymphocyte mAChRs receptor density
(Bmax) increased 73-95% after treatment
with 0.5 mg/kg/day and 150-198% after
treatment with 2 mg/kg/day.
In contrast with the effect on receptor
binding in brain tissue, the changes induced
by MeHg in lymphocytes were present imme-
diately at the end ofthe exposure period and
were still observable 14 days after termination
oftreatment (Figure 2). Analyses ofdata from
saturation curves of [3H]QNB binding
(Figure 3) clearly illustrate the different pat-
tern and regional selectivity ofthe response to
MeHg with changes in receptor density that
developed earlier and were more pronounced
in lymphocytes than in brain tissue.
As in the brain, the affinity oflymphocyte
mAChRs (Kd) was not affected by MeHg
treatment, and the Hill coefficients (nH) were
close to unit (0.92-1.14) in both control and
MeHg-treated rats (Tables 1 and 2).
Discussion
In this study, prolonged exposure of rats
to MeHg at a daily dose as low as 0.5
mg/kg caused molecular changes involving
300 i
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Figure 1. Binding characteristics of muscarinic receptor in the cerebellum of rats treated with MeHg.
Saturation curves of [3H]QNB binding in animals sacrificed (A) immediately at the end of a 16-day expo-
sure period or (B) 14 days after termination of treatment. Tissue preparations were incubated with
increasing concentrations of the radioligand alone (total binding) or plus atropine (10-5 M) to define non-
specific binding. Specific binding was obtained by subtracting nonspecific from total binding. The differ-
ent curve profiles in (A) and (B) highlight the delayed effect of MeHg exposure on cerebellar receptor
binding. Postexposure data (B) shows that curve profiles for MeHg-treated rats are different (p < 0.05)
from the control curve. Values are the means of triplicate determinations from a representative experi-
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Figure 2. Muscarinic receptor binding in splenic lymphocytes after treatment with MeHg. Saturation
curves of[3H]QNB binding in animals (A) sacrificed immediately atthe end of a 16-day exposure period or
(B) 14 days after termination of treatment. Curve profiles for MeHg-treated rats are different (p < 0.05)
from the control curve. Values are the means of triplicate determinations from a representative experi-















Lymphocytes Cerebral Hippocampus Cerebellum
cortex
Figure 3. Percentage increase in Bmax (A) at the
end of the 16-day MeHg treatment (values are the
mean derived from three different experiments)
and (B) at 14 days after termination of MeHg expo-
sure (values are the mean derived from two differ-
ent experiments). Bmax is expressed as fmol/mg
protein (brain) orfmol/106 cells (lymphocytes).
*p < 0.05, statistically different within a single experiment
comparing the [3H]QNB saturation curve from MeHg-
treated rats with its concurrent control curve.
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cholinergic receptors in brain and lympho-
cytes. These findings are discussed in rela-
tion to the effects of MeHg on the nervous
system and in relation to perspectives in the
area ofmarkers ofsubclinical MeHg toxicity.
The cholinergic system andMeHg neuro-
toxicity. MeHg ingestion caused selective
increases in mAChR density in two rat brain
regions (hippocampus and cerebellum) with-
out affecting receptor affinity. These findings
agree with earlier in vitro studies describing
the alteration of muscarinic receptor binding
characteristics in rat brain preparations treated
with MeHg (12). The MeHg action on cere-
bral mAChRs was delayed in onset. Increase
in receptor density was not demonstrable
immediately after termination ofexposure but
was invariably seen in the animals examined 2
weeks after the end ofexposure.
Because cholinergic systems play an
important role in learning and memory
processes (35), the increased mAChR densi-
ty caused by MeHg in brain tissue may be a
deleterious process. The MeHg-induced
changes in cerebral mAChR density were
regionally specific. The cerebellum, a prima-
ry target for MeHg neurotoxicity, was the
most susceptible area showing delayed recep-
tor changes even at the lower 0.5 mg/kg/day
MeHg dose. Hippocampal mAChR density
was increased 14 days after exposure to 2
mg/kg/day MeHg, whereas cerebrocortical
receptors were not affected at either dosing
regimen. Several studies report selective or
focal brain damage as a typical response to
MeHg in both laboratory animals (27) and
humans (1). Autoradiographic experiments
in mice have shown that MeHg accumulates
preferentially in the hippocampus and cere-
bellum (36-38), suggesting that the
observed cerebral mAChR changes correlate
to the concentration of MeHg in particular
brain regions.
Experiments indicating that MeHg slow-
ly accumulates in the rat brain during con-
tinuous low-level exposure provide one
explanation for the late appearance of cere-
bral mAChR changes in the MeHg-treated
rats (39). It has also been suggested that the
development of some neurologic effects of
MeHg depends not only on the ability of
MeHg to attain effective concentrations in
brain tissue but also on the length of time
they are maintained (40). The absorbed
MeHg requires several weeks for removal
from the rat brain (16,39). Adaptive changes
involving mAChRs in the target organ may
occur after prolonged overexposure to
MeHg. Neurotransmitter receptors are regu-
lated by homeostatic mechanisms that com-
pensate for changes in the amount ofagonist
or antagonist to which they are exposed
(22,23). For example, although mAChRs
overstimulation induces a receptor density
decrease (down-regulation), prolonged treat-
ments with muscarinic antagonists (e.g.,
atropine) cause receptor increase (up-regula-
tion) and supersensitivity to muscarinic ago-
nists (22). Thus, the delayed effect ofMeHg
in the rat brain might be attributable to a
combination of factors. Gradual accumula-
tion of MeHg in brain tissue and up-regula-
tion of cerebral mAChRs may occur during
chronic MeHg exposure to compensate for
early stage effects such as a) MeHg-induced
inhibition ofACh synthesis (13) and conse-
quent reduction ofbrain ACh levels (14,15),
and b) direct (atropinelike) competitive
antagonism by MeHg on mAChRs (10-12).
It is increasingly evident that adaptation of
neurotransmitter receptors may be a primary
mechanism mediating the long-term actions
of drugs and chemicals in the central ner-
vous system (41).
Our findings in adult rats differ from
observations in the immature rat brain where
MeHg decreased and did not increase
[3H]QNB binding (16). In pregnant rats, a
single dose of 8 mg/kg MeHg by gavage on
day 15 of gestation temporarily reduced the
density ofcerebrocortical mAChRs in the off-
spring (16). The effect was observed in the
brain of 14- and 21-day-old animals but was
not present in 60-day-old rats in which the
concentrations ofmercury in the cerebral cor-
tex had returned to normal. In the developing
rat brain, mAChRs appear between gestation-
al days 16 and 18 (42). Their density increas-
es gradually after birth, reaching adult levels at
approximately 30-45 days of age (43,44).
Therefore, it seems that MeHg inhibits the
development ofmAChRs when administered
before they appear. Perhaps the postulated
up-regulation mechanism, which in the adult
compensates for the complex interactions of
MeHg with the cholinergic system, is not
functional in the immature brain.
Muscarinic cholinergic receptors as bio-
markers. It is increasingly evident that bio-
chemical and molecular parameters similar
to those involved as targets for toxicants in
the central nervous system are also present in
more easily accessible tissues, for example,
peripheral blood cells (45). Examples include
neurotransmitter metabolizing enzymes, sec-
ond messengers, high-affinity uptake sys-
tems, and neurotransmitter receptors such as
mAChRs expressed not only in the nervous
system but also in peripheral blood lympho-
cytes in rats (18) and in humans (20).
Because circulating lymphocytes can be easi-
ly and ethically obtained from humans and
because they can be sampled repeatedly over
prolonged chemical exposure, strategies
using these peripheral samples as surrogate
indicators offer the advantage of exploring
early effects ofneurotoxicants by convenient
noninivasive methods (46).
In rats exposed to MeHg, significant
increases in mAChR density were found not
only in hippocampus and cerebellum but
also in splenic lymphocytes. The receptor
increase in lymphocytes was even more pro-
nounced (up to 198% vs. 20-44%) and
more rapid in onset than that in brain tissue.
There was no temporal correlation for the
receptor changes occurring in MeHg
response in brain and lymphocytes. The rea-
son for this discrepancy is not evident. In
rats, prolonged low-level administration of
MeHg caused higher (up to 10-fold) mercury
levels in the spleen than in brain (47). In
chronic exposure, the effective MeHg con-
centration required to modify mAChRs den-
sity may be more rapidly attained in periph-
eral lymphocytes than in the less accessible
brain tissue where the rates of access and
accumulation of MeHg are limited by the
blood-brain barrier.
Muscarinic receptors belong to a multi-
genic family that codes for at least five recep-
tor subtypes (48). At control levels, [3H]QNB
displayed a lower affinity in lymphocytes than
in brain tissue, confirming previous observa-
tions (21). A possible explanation for this
finding would be that the subtypes of
mAChRs expressed in lymphocytes are differ-
ent than in brain. Current knowledge of the
interaction of MeHg with these heteroge-
neous receptor subpopulations is limited. In
rat brain, MeHg affects binding characteris-
tics ofmAChRs ofthe Ml and M2 subtypes
(12). M2 receptors have been identified in
lymphocytes from rats (22,46,49) and
humans (20,50). Studies examining the inter-
action ofMeHg with subtypes oflymphocyte
muscarinic receptors would be helpful to
establish whether the muscarinic cholinergic
recognition sites expressed in peripheral tis-
sues are representative of the corresponding
molecular parameters present in the central
nervous system.
The interaction ofMeHg with mAChRs
in lymphocytes may have important implica-
tions not only in relation to biomarkers but
also from an immunologic viewpoint. The
immunotoxic potential of mercury com-
pounds has become a subject of great inter-
est (51). Lymphocyte mAChRs respond to
cholinergic stimulation with altered mem-
brane fluidity and modification of immune
function (52).
In conclusion, prolonged ingestion of
low doses ofMeHg in rats causes subtle mol-
ecular changes with adaptive imbalance of
mAChRs in the hippocampus and cerebel-
lum, perhaps through an up-regulation
mechanism. The onset ofthe effect ofMeHg
is delayed and is preceded by a marked
increase in density of mAChRs expressed in
splenic lymphocytes. Because it is impossible
to routinely assess neurotransmitter receptor
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function in the mammalian nervous system
in vivo, mAChRs in peripheral blood lym-
phocytes may be convenient surrogate indica-
tors ofanalogous receptor changes occurring
in brain after prolonged exposure to MeHg
or to other toxicants that affect mAChRs in
the central nervous system. Additionally, the
effect of low doses of MeHg on lymphocyte
mAChRs indicates that this receptor system
should be investigated further as a possible
target for MeHg immunotoxicity.
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